Despite the availability of numerous antistaphylococcal drugs, the treatment of severe staphylococcal infections remains a major therapeutic challenge. A new class of antimicrobial agents, the fluoroquinolones, is under development. These drugs are consistently active against both methicillin-or oxacillin-susceptible (OS) and methicillin-or oxacillin-resistant (OR) staphylococci (2, 8, 9, 20, 26) . In this study, we compared the in vitro antistaphylococcal activity of one fluoroquinolone, pefloxacin, alone and in combination with other drugs, with the antistaphylococcal activities of other drugs and drug combinations.
MATERIALS AND METHODS
Organisms. Staphylococci were clinical isolates identified by using a profile of 27 biochemical tests and the interpretive criteria of Kloos and Schleifer (13) . Included were 50 strains each of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus haemolyticus and 25 strains each of Staphylococcus hominis and Staphylococcus saprophyticus. Half of the S. aureus, S. epidermidis, and S. haemolyticus strains and all of the S. hominis and S. saprophyticus strains were OS; the others were OR.
MICs. Laboratory standards of oxacillin, cephalothin, pefloxacin, vancomycin, gentamicin, erythromycin, clindamycin, doxycycline, and trimethoprim-sulfamethoxazole were supplied by the manufacturers, diluted according to instructions, and dispensed into microdilution plates using an MIC-2000 Plus dispensing machine (Dynatech Laboratories, Inc., Alexandria, Va.) in log2 dilution steps within the range of 0.06 to 64 ,ug/ml. MICs were determined by a standardized microdilution method (18) in 0.1-ml volumes of cation-supplemented Mueller-Hinton broth (Difco Laboratories, Detroit, Mich.). For oxacillin and cephalothin, 2% NaCl was added to the medium (18) . Trimethoprimsulfamethoxazole was tested in a fixed 1:19 ratio; 0. 4 ,ug/ml and 0.13 to 1 pug/ml; oxacillin, 16 pLg/ml and 0.13 to 0.5 ,ug/ml; vancomycin, 8 ,ug/ml and 0.5 to 2 ,ug/ml; rifampin, 1 and -0.06 ,ug/ml; gentamicin, 4 ,ug/ml and 0.13 or -2 ,ug/ml. Incubation was at 35°C in a shaker water bath. Quantitative subcultures were performed after 0, 6, and 24 h of incubation to determine CFU per milliliter. At those times, 0.1-ml volumes of undiluted and serially diluted 1:10 portions were dispersed into 6-ml Mueller-Hinton agar pour plates. Antimicrobial dilution was 1:600 in the 10-2 plate, which ensured that a fourfold or greater log10 reduction in CFU per milliliter could be detected for all drug-organism combinations despite antibiotic carry-over. The plates were incubated at 35°C for 48 h before the colonies were counted. Table 1 . For each species, there was a typical unimodal distribution of oxacillin and cephalothin MICs for OS and OR strains. Pefloxacin, vancomycin, and rifampin were equally active against OS and OR strains and also had unimodal distributions of MICs.
The susceptibilities of staphylococci to gentamicin, erythromycin, clindamycin, doxycycline, and trimethoprimsulfamethoxazole are shown in Table 2 . The distribution of MICs for these drugs was usually bimodal, although some organisms were uniformly susceptible to some drugs. In all instances, OR strains were more likely to be resistant to these drugs than were OS strains.
All eight drug combinations were indifferent in inhibitory activity against 55 of the 60 strains tested. For five strains of OR (MICs, >16 ,ug/ml), gentamicin-resistant (MICs, .8 p.g/ml) staphylococci (one S. aureus strain, three S. epidermidis strains, and one S. haemolyticus strain), there was synergy between oxacillin and gentamicin; all the strains were inhibited by 2 to 4 ,ug of both drugs per ml in combination.
Killing kinetics. The killing effects of various drugs and drug combinations with staphylococci are shown in Table 3 ; consistent results were observed for each drug-organism combination. The (17, 19, 25) , enhanced reduction of bacteria in experimentally induced endocardial vegetations in rabbits (17, 19) , and the results of some studies which indicated improved efficacy in patients with endocarditis (12, 14, 15) . The addition of rifampin has also been justified based on improved efficacy despite frequently observed in vitro antagonism (1, 3, 12, 15, 24) . In vitro, the major benefit of adding rifampin to penicillins or vancomycin has been a reduction in the emergence of rifampin resistance; unfortunately, this has not been a consistent observation in vivo (1, 3, 7) . It has been postulated that the favorable clinical results observed with rifampin combinations are due to the ability of rifampin to concentrate within phagocytic cells and kill intracellular staphylococci (16) . Resistance to the fluoroquinolones has also been observed during treatment of patients with difficult-to-eradicate staphylococcal infections (5, 10) , and these drugs, like rifampin, are concentrated in human neutrophils where they are lethal to staphylococci (6) . The fluoroquinolones have been consistently active in vitro against the most common species of clinically significant staphylococci. Unlike most other antistaphylococcal drugs, they were equally active against OS and OR strains (2, 8, 9, 20, 26 Other studies with fluoroquinolones and S. aureus have had similar results. Ciprofloxacin was more rapidly bactericidal than vancomycin (2, 20) or rifampin (2) , ciprofloxacin plus gentamicin or amikacin was often synergistic (21), ciprofloxacin plus rifampin was antagonistic when the concentration of either drug was higher than the MIC (22) , and ciprofloxacin plus vancomycin was not more bactericidal than ciprofloxacin alone (20) . When sera spiked with ciprofloxacin, pefloxacin, nafcillin, or vancomycin were tested for bactericidal activity against OS S. aureus, the fluoroquinolones were more rapidly bactericidal than nafcillin or vancomycin. The bactericidal activity of these sera was reduced by the addition of rifampin; this antagonism was also reflected in reduced serum bactericidal titers with nafcillin but not vancomycin, ciprofloxacin, or pefloxacin (11) . When postinfusion sera from volunteers given intravenous pefloxacin, amikacin, or both were tested for bactericidal activity against OS S. aureus, amikacin was more bactericidal than pefloxacin; the combination usually had intermediate activity when compared with the individual drugs. Serum inhibitory and bactericidal titers for the three regimens were essentially the same. When OR S. aureus was tested, results were somewhat different, but it was unclear whether the strains tested were amikacin susceptible or amikacin resistant (23) .
The results of this study indicate that pefloxacin is a potentially useful antistaphylococcal drug. When treating VOL. 31, 1987 infections caused by OS or OR strains of S. aureus, S. epidermidis or S. haemolyticus, combinations with aminoglycosides or rifampin are reasonable for testing clinical efficacy, based on reasoning analogous to that used for combinations of oxacillin or vancomycin with those drugs.
